228 related articles for article (PubMed ID: 16608091)
1. [Investigating the fluoroquinolone molecular resistant mechanism of Stenotrophomonas maltophilia].
Tao CM; Lü XJ; Li P
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 37(2):266-9. PubMed ID: 16608091
[TBL] [Abstract][Full Text] [Related]
2. Mutations in gyrA and parC QRDRs are not relevant for quinolone resistance in epidemiological unrelated Stenotrophomonas maltophilia clinical isolates.
Ribera A; Doménech-Sanchez A; Ruiz J; Benedi VJ; Jimenez de Anta MT; Vila J
Microb Drug Resist; 2002; 8(4):245-51. PubMed ID: 12523620
[TBL] [Abstract][Full Text] [Related]
3. Preservation of topoisomerase genetic sequences during in vivo and in vitro development of high-level resistance to ciprofloxacin in isogenic Stenotrophomonas maltophilia strains.
Valdezate S; Vindel A; Saéz-Nieto JA; Baquero F; Cantón R
J Antimicrob Chemother; 2005 Jul; 56(1):220-3. PubMed ID: 15928010
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of decreased susceptibility to fluoroquinolones in avian Salmonella serovars and their mutants selected during the determination of mutant prevention concentrations.
Kehrenberg C; de Jong A; Friederichs S; Cloeckaert A; Schwarz S
J Antimicrob Chemother; 2007 May; 59(5):886-92. PubMed ID: 17369276
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase II and IV quinolone resistance-determining regions in Stenotrophomonas maltophilia clinical isolates with different levels of quinolone susceptibility.
Valdezate S; Vindel A; Echeita A; Baquero F; Cantó R
Antimicrob Agents Chemother; 2002 Mar; 46(3):665-71. PubMed ID: 11850246
[TBL] [Abstract][Full Text] [Related]
7. An unusually high level of quinolone resistance associated with type II topoisomerase mutations in quinolone resistance-determining regions of Aeromonas caviae isolated from diarrhoeal patients.
Sinha S; Chattopadhyay S; Bhattacharya SK; Nair GB; Ramamurthy T
Res Microbiol; 2004 Dec; 155(10):827-9. PubMed ID: 15567276
[TBL] [Abstract][Full Text] [Related]
8. Resistance of different Chlamydia-like organisms to quinolones and mutations in the quinoline resistance-determining region of the DNA gyrase A- and topoisomerase-encoding genes.
Casson N; Greub G
Int J Antimicrob Agents; 2006 Jun; 27(6):541-4. PubMed ID: 16697560
[TBL] [Abstract][Full Text] [Related]
9. Alterations in the GyrA and GyrB subunits of topoisomerase II and the ParC and ParE subunits of topoisomerase IV in ciprofloxacin-resistant clinical isolates of Pseudomonas aeruginosa.
Lee JK; Lee YS; Park YK; Kim BS
Int J Antimicrob Agents; 2005 Apr; 25(4):290-5. PubMed ID: 15784307
[TBL] [Abstract][Full Text] [Related]
10. In vitro induction and selection of fluoroquinolone-resistant mutants of Streptococcus pyogenes strains with multiple emm types.
Billal DS; Fedorko DP; Yan SS; Hotomi M; Fujihara K; Nelson N; Yamanaka N
J Antimicrob Chemother; 2007 Jan; 59(1):28-34. PubMed ID: 17065188
[TBL] [Abstract][Full Text] [Related]
11. Mutations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in clinical strains of fluoroquinolone-resistant Shigella in Anhui, China.
Hu LF; Li JB; Ye Y; Li X
J Microbiol; 2007 Apr; 45(2):168-70. PubMed ID: 17483803
[TBL] [Abstract][Full Text] [Related]
12. The acquisition of full fluoroquinolone resistance in Salmonella Typhi by accumulation of point mutations in the topoisomerase targets.
Turner AK; Nair S; Wain J
J Antimicrob Chemother; 2006 Oct; 58(4):733-40. PubMed ID: 16895934
[TBL] [Abstract][Full Text] [Related]
13. Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism.
Beeton ML; Chalker VJ; Kotecha S; Spiller OB
J Antimicrob Chemother; 2009 Sep; 64(3):529-38. PubMed ID: 19567408
[TBL] [Abstract][Full Text] [Related]
14. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis.
Saito R; Sato K; Kumita W; Inami N; Nishiyama H; Okamura N; Moriya K; Koike K
J Antimicrob Chemother; 2006 Sep; 58(3):673-7. PubMed ID: 16870650
[TBL] [Abstract][Full Text] [Related]
15. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
Yun HJ; Min YH; Jo YW; Shim MJ; Choi EC
Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
[TBL] [Abstract][Full Text] [Related]
16. Study of isolation of fluoroquinolone-resistant Ureaplasma urealyticum and identification of mutant sites.
Zhang W; Wu Y; Yin W; Yu M
Chin Med J (Engl); 2002 Oct; 115(10):1573-5. PubMed ID: 12490114
[TBL] [Abstract][Full Text] [Related]
17. Fluoroquinolone resistance and gyrA and parC mutations of Escherichia coli isolated from chicken.
Lee YJ; Cho JK; Kim KS; Tak RB; Kim AR; Kim JW; Im SK; Kim BH
J Microbiol; 2005 Oct; 43(5):391-7. PubMed ID: 16273029
[TBL] [Abstract][Full Text] [Related]
18. Accumulation of mutations in DNA gyrase and topoisomerase IV genes contributes to fluoroquinolone resistance in Vibrio cholerae O139 strains.
Zhou Y; Yu L; Li J; Zhang L; Tong Y; Kan B
Int J Antimicrob Agents; 2013 Jul; 42(1):72-5. PubMed ID: 23643392
[TBL] [Abstract][Full Text] [Related]
19. Rapid detection of gyrA and parC mutations in quinolone-resistant Salmonella enterica using Pyrosequencing technology.
Hopkins KL; Arnold C; Threlfall EJ
J Microbiol Methods; 2007 Jan; 68(1):163-71. PubMed ID: 16934351
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of point mutations in the ygeD, gyrA and parC genes in fluoroquinolones resistant clinical isolates of Chlamydia trachomatis].
Misiurina OIu; Shipitsina EV; Finashutina IuP; Lazarev VN; Akopian TA; Savicheva AM; Govorun VM
Mol Gen Mikrobiol Virusol; 2004; (3):3-7. PubMed ID: 15354934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
